Amy Legg

👏CRE RESPOND is thrilled to announce the Sepsis: What is the Latest Data for Optimal Management of Sepsis
seminar!👏

🗓️When: Thursday 16 October, 12pm-1pm (AEST)
🗺️Where: UQCCR (or online!)

REGISTER HERE: bit.ly/3VBLeSx

Don't miss out on the chance to hear from expert clinicians and researchers!

Thank you!! 💕

The whole team at CRE RESPOND are very proud of our very own Amy Legg on her graduation!

Congratulations Amy!! 👏🎉

@leggwamy.bsky.social

@crerespond.bsky.social

Graduation nation! Huge thanks to the supers @gurujosh.bsky.social @steventong.bsky.social Jane Davies, Jason Roberts. Look after your kidneys guys!

YouTube video by cre.respond 03 Dr Andrew Burke - Therapeutic Drug Monitoring in Non-Tuberculous Mycobacteria

🤩Dr Andrew Burke's recent presentation on 'Therapeutic Drug Monitoring in Non-Tuberculous Mycobacteria' was not one to miss...

📢Luckily, even if you weren't able to attend the Respiratory Infections seminar, you won't have to!

youtu.be/V2nITG_rxp8?...

Congratulations Elise Mitri from NACE, Austin Health & The Peter Doherty Institute presenting the iNAAN Trial results - > 5000 pts & 1500 inpatient #penicillinallergy DOC performed. Safe irrespective of stakeholder with significant prescribing gains. Largest inpatient penicillin allergy study 👏🎉

On 7 August 2025, we will be hosting our Worldwide Precision Dosing seminar for the fifth year!💉

📢Chaired by Dr Amy Legg, a clinical pharmacist at RBWH, this event explores individualised drug therapy.

To find out more about this event and register: bit.ly/3GtrIUb

@leggwamy.bsky.social
#UQCCR

Always happy to celebrate you @minyonavent.bsky.social ❤️ what a packet of legends

✨Hello and welcome to the official CRE Respond page!✨

CRE RESPOND aims to reduce the burden of antimicrobial resistance through optimal personalised dosing. 💊

🚨Follow us to stay up to date with our educational events and the latest goings-on in the world of anti-microbial optimisation!

#uqccr

Elise Mitri presenting work on safely delabeling patients with penicillin allergy at the ESCMID Global conference.

Congrats to @elisemitri.bsky.social, @trubianojason.bsky.social et al for their great work on safely delabeling patients with #penicillinallergy. Elise presenting their prospective, pharmacist-led program live at #ESCMIDGlobal
#IDSky #PharmSky #openacess

www.cmi-comms.com/article/S295...

#SNAPtrial will answer this question in a large RCT (rather than observational). Come to ESCMID global and hear the results!

Approaching more than all previous SAB trials combined! What next?!

Population pharmacokinetics: from fundamentals to clinical practice Are you looking to enhance your knowledge of pharmacokinetics (PK) and gain hands-on experience with population pharmacokinetic (popPK) modelling? Whether you are new to the field or looking to deepen...

Interested in PK modelling? CRE RESPOND is running its Population Pharmacokinetics workshop, from fundamentals to clinical practice. Much more practical program this year! Be quick spaces are limited.
Register here: bit.ly/3ElRmJ6

Some things never change and some things change heaps!! Addit: I am ready for your Grey’s rewatch podcast…

Thanks for sharing this and my sincere condolences to the whole group. Dr Engel has a personal and professional legacy to be proud of 💕

Protamine protects against vancomycin-induced kidney injury | Antimicrobial Agents and Chemotherapy Vancomycin is one of the most widely used antibiotics within United States in-patient healthcare systems, accounting for 11.9% of all antibiotic use for inpatient antimicrobials (1,258 out of 10,612) ...

Really excited by this article from @idpharmacometrx.bsky.social et al. Protamine as the prototype for megalin blockade to reduce/delay kidney accumulation of vanc (and maybe colistin and aminoglycosides…). But also an excellent VIKI overview, fab pics 💕
journals.asm.org/doi/10.1128/...

I learnt to name studies from the best!

What a program! Excellent

🆕💫Retrospective cohort study #CMI
AKI is a frequent complication of S. aureus bacteraemia and is associated with 30-day mortality
Not “a cute” complication: phenotypic analysis of acute kidney injury in S. aureus bacteraemia #idsky #EMIMCC
www.clinicalmicrobiologyandinfection.com/article/S119...

**Starting 2025 with a key update:
The new ATS/CDC/ERS/IDSA guidelines on treating drug-susceptible and drug-resistant tuberculosis (TB) are out!
What do you think about these changes? How will they shape clinical practice moving forward?**
#idsky #tbsky #EMIMCC

Pharmacodynamic studies indicate that anaerobic killing is optimized when the plasma AUC) to MIC ratio is ≥70:1; the probability of achieving this target with 1000mg/d of metronidazole is > 99% against B. fragilis that exhibit MICs < 2mg/L #idsky #medsky #EMIMCC

🆕🔥Retrospective, multicenter, inverse probability-of-treatment weighted cohort study
Among hospitalized patients with septic shock, there was no difference between cefepime and piperacillin-tazobactam on the occurrence of severe AKI #idsky #medsky
academic.oup.com/cid/advance-...

Worldwide Precision Dosing Seminar CRE RESPOND's fourth Annual Worldwide Precision Dosing seminar was held on Tuesday 10 September.  Our panel of expert clinicians and clinical educators, from America, Europe and Australia, covered whe...

Just in case you missed it Dr Emily Heil and Dr Julie Ann Justo with the greatest overview of aminoglycoside dosing for #UQCCR earlier this year! All the recordings here cre-respond.centre.uq.edu.au/event/sessio...